Poster | Myllia’s VISTA platform for unbiased target discovery in primary human DCs and macrophages
With a focus on immune cells, Myllia’s VISTA™ platform enables the discovery of high-value drug targets and deep insights into immune cell function, including primary human dendritic cells (DCs) and macrophages.
VISTA™ enables unbiased CRISPR perturbations in primary human macrophages and dendritic cells, combined with single-cell readouts to map gene function at unprecedented depth and precision. It captures the biology where it really happens – in primary human cells – and facilitates unbiased CRISPR screens at genome-scale. This platform opens vast opportunities for identifying novel drug targets across a broad spectrum of immune-related diseases.
Download the poster showcasing Myllia’s VISTA platform here: